Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits.
Research Department, Ciba-Geigy Corporation, Summit, NJ 07901, USA.
E M
EM
O'Byrne
D T
DT
Parker
E D
ED
Roberts
R L
RL
Goldberg
L J
LJ
MacPherson
V
V
Blancuzzi
D
D
Wilson
H N
HN
Singh
R
R
Ludewig
V S
VS
Ganu
D000818:Animals; D002358:Cartilage, Articular / Q000378:metabolism / Q000473:pathology*; D006614:Hindlimb / Q000473:pathology; D006877:Hydroxamic Acids; D007596:Joints / Q000473:pathology; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D010003:Osteoarthritis / Q000473:pathology / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011509:Proteoglycans / Q000378:metabolism*; D011719:Pyrazines; D011817:Rabbits; D013449:Sulfonamides
C097658:CGS 27023A; D006877:Hydroxamic Acids; D011480:Protease Inhibitors; D011509:Proteoglycans; D011719:Pyrazines; D013449:Sulfonamides; D008666:Metalloendopeptidases